View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsscPharmaceuticals 将来の成長Future 基準チェック /56scPharmaceuticalsは、70.3%と34%でそれぞれ年率70.3%で利益と収益が成長すると予測される一方、EPSはgrowで70.5%年率。主要情報70.3%収益成長率70.53%EPS成長率Pharmaceuticals 収益成長23.7%収益成長率34.0%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日07 Oct 2025今後の成長に関する最新情報お知らせ • Jan 11scPharmaceuticals Inc. Provides Preliminary FUROSCIX Net Revenue Guidance for the Fourth Quarter and Full Year 2024scPharmaceuticals Inc. provided preliminary FUROSCIX net revenue guidance for the fourth quarter and full year 2024. The company expected preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12.0 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range. Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range.Breakeven Date Change • Mar 27Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 31% per year to 2025. The company is expected to make a profit of US$39.9m in 2026. Average annual earnings growth of 60% is required to achieve expected profit on schedule.お知らせ • Jan 05scPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023scPharmaceuticals Inc. provided revenue guidance for the full year 2023. For the period, the company anticipates net revenue to be in a range of $13.4 million to $13.6 million.Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.4m in 2026. Average annual earnings growth of 57% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 11Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$4.74m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.Breakeven Date Change • May 12Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.77m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Oct 18scPharmaceuticals Inc. Files Form 15scPharmaceuticals Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.お知らせ • Oct 09scPharmaceuticals Inc.(NasdaqGM:SCPH) dropped from NASDAQ Composite IndexscPharmaceuticals Inc. has been dropped from the NASDAQ Composite Index .お知らせ • Oct 08MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH).MannKind Corporation (NasdaqGM:MNKD) entered into a definitive Agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. As on October 6, 2025, the tender offer expired and pursuant to the offer 73.47% shares where validly tendered. Jefferies LLC acted as financial advisor for MannKind Corporation. The team of Cooley LLP led by Barbara Borden, Rowook Park, Julia Kim, Mischi a Marca and Adam Longenbach acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. The team of Latham & Watkins LLP led by Wesley Holmes, Scott Shean, Bret Stancil, Elisabeth Martin, Peter Handrinos, Alexandra McArthur, Josh Friedman, Katharine Moir, Betty Pang, Chad Jennings, Elizabeth Ohacted, Heather Deixler, Patrick English, Kristin Murphy and Steven Chinowsky as legal advisor for scPharmaceuticals Inc. MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH) on October 7, 2025.お知らせ • Oct 07+ 20 more updatesscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from NASDAQ Biotechnology IndexscPharmaceuticals Inc removed from NASDAQ Biotechnology Index.お知らせ • Aug 25MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million.MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. Jefferies LLC acted as financial advisor for MannKind Corporation. Barbara Borden and Rowook Park of Cooley LLP acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. Scott Shean, Wesley Holmes and Bret Stancil of Latham & Watkins LLP acted as legal advisor for scPharmaceuticals Inc.お知らせ • Aug 14scPharmaceuticals Inc. Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111scPharmaceuticals Inc. announced that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.お知らせ • Aug 01scPharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025scPharmaceuticals Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025お知らせ • May 08scPharmaceuticals Inc. to Report Q1, 2025 Results on May 14, 2025scPharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025お知らせ • Apr 22scPharmaceuticals Inc., Annual General Meeting, Jun 03, 2025scPharmaceuticals Inc., Annual General Meeting, Jun 03, 2025.お知らせ • Mar 13scPharmaceuticals Inc. to Report Q4, 2024 Results on Mar 19, 2025scPharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 19, 2025お知らせ • Mar 07scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX®? Indication to Include the Treatment of Edema in Patients with Chronic Kidney DiseasescPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX®? to expand the indication to include treatment of edema in patients with chronic kidney disease (CKD). FUROSCIX (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the treatment of edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.お知らせ • Jan 11scPharmaceuticals Inc. Provides Preliminary FUROSCIX Net Revenue Guidance for the Fourth Quarter and Full Year 2024scPharmaceuticals Inc. provided preliminary FUROSCIX net revenue guidance for the fourth quarter and full year 2024. The company expected preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12.0 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range. Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range.Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.40 loss in 3Q 2023)Third quarter 2024 results: US$0.75 loss per share (further deteriorated from US$0.40 loss in 3Q 2023). Revenue: US$10.0m (up 164% from 3Q 2023). Net loss: US$35.1m (loss widened 125% from 3Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Nov 07scPharmaceuticals Inc. to Report Q3, 2024 Results on Nov 13, 2024scPharmaceuticals Inc. announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.37 loss in 2Q 2023)Second quarter 2024 results: US$0.44 loss per share (further deteriorated from US$0.37 loss in 2Q 2023). Revenue: US$8.05m (up 392% from 2Q 2023). Net loss: US$17.1m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.New Risk • Aug 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 34% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (34% increase in shares outstanding).お知らせ • Aug 13+ 1 more updatescPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $49.9995 million.scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $49.9995 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $4 Discount Per Security: $0.24 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 500,000 Price\Range: $3.999 Discount Per Security: $0.24お知らせ • Aug 12scPharmaceuticals Inc. has filed a Follow-on Equity Offering.scPharmaceuticals Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-funded Warrants Security Type: Equity Warrantお知らせ • Jul 25scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney DiseasescPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. In Type D meeting feedback provided by the FDA last year, the agency confirmed that no additional clinical studies would be needed to expand the indication, provided that the Company is able to demonstrate an adequate pharmacokinetic (PK) and pharmacodynamic (PD) bridge to the listed drug, furosemide injection, 10 mg/mL. FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use: FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of FUROSCIX. IMPORTANT SAFETY INFORMATION: FUROSCIX is contraindicated in patients with anuria, patients with a history of hypersensitivity to furosemide or medical adhesives and in patients with hepatic cirrhosis or ascites. Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital. Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.New Risk • May 15New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$60m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$60m). Share price has been volatile over the past 3 months (8.4% average weekly change).お知らせ • May 09scPharmaceuticals Inc. to Report Q1, 2024 Results on May 14, 2024scPharmaceuticals Inc. announced that they will report Q1, 2024 results on May 14, 2024お知らせ • Apr 28scPharmaceuticals Inc., Annual General Meeting, Jun 11, 2024scPharmaceuticals Inc., Annual General Meeting, Jun 11, 2024, at 12:30 US Eastern Standard Time. Agenda: To elect three Class I directors, namely Frederick Hudson, Leonard D. Schaeffer and Sara Bonstein, each to hold office until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, or until their earlier death, resignation or removal; to ratify the appointment of RSM US LLP as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on an advisory (non-binding) basis, the compensation of company's named executive officers; to approve an amendment to the Second Amended and Restated Certificate of Incorporation to provide for the exculpation of officers from certain breaches of fiduciary duty to the extent permitted by the General Corporation Law of the State of Delaware; and to transact any other business that properly comes before the Annual Meeting (including any continuation, adjournment or postponement thereof).Board Change • Apr 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director William Abraham was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 25scPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) InjectionscPharmaceuticals Inc. announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector. The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility. If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.Breakeven Date Change • Mar 27Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 31% per year to 2025. The company is expected to make a profit of US$39.9m in 2026. Average annual earnings growth of 60% is required to achieve expected profit on schedule.お知らせ • Mar 14scPharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $50 million.scPharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 07scPharmaceuticals Inc. to Report Q4, 2023 Results on Mar 13, 2024scPharmaceuticals Inc. announced that they will report Q4, 2023 results on Mar 13, 2024お知らせ • Jan 05scPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023scPharmaceuticals Inc. provided revenue guidance for the full year 2023. For the period, the company anticipates net revenue to be in a range of $13.4 million to $13.6 million.Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.4m in 2026. Average annual earnings growth of 57% is required to achieve expected profit on schedule.お知らせ • Nov 02scPharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023scPharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 08, 2023New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (US$3.7m revenue).お知らせ • Sep 20Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth InitiativesscPharmaceuticals Inc. announced that the Company has received positive feedback from the U.S. Food and Drug Administration (FDA) on two key long-term growth initiatives. The Company announced FDA feedback from a Type C meeting pertaining to the development of an 80mg/1mL auto-injector intended to provide an additional option to the on-body infusor for treatment of congestion due to fluid overload in eligible adult patients who do not require hospitalization. The Company expects that an auto-injector, if successfully developed and approved, would reduce manufacturing costs compared to the current on-body infusor and confer environmental advantages. scPharmaceuticals plans to report data from a pivotal pharmacokinetic (PK) study in first half of 2024, and, if successful, targets submitting a Supplemental New Drug Application (sNDA) to the FDA by the end of 2024. The Company also announced feedback from a Type D meeting with the FDA pertaining to the potential expansion of the FUROSCIX label to include treatment of edema due to fluid overload in patients with CKD. In its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication, provided that the Company demonstrates an adequate PK and pharmacodynamic bridge to the listed drug, furosemide injection, 10 mg/mL. CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.Breakeven Date Change • Aug 11Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$4.74m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.お知らせ • Aug 04scPharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023scPharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023お知らせ • Aug 03scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication ExpansionscPharmaceuticals Inc. announced that the Company has received positive Type C meeting feedback from the US Food and Drug Administration (FDA) regarding the potential expansion of the FUROSCIX(R) indication to allow for use in New York Heart Association (NYHA) Class IV heart failure patients. FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure. The Company also announced the issuance of U.S. patents covering concentrated formulations of furosemide. This enables the possibility of developing additional furosemide formulations for subcutaneous administration that will provide clinicians with additional dosing flexibility. The Company has completed initial solubility and stability studies on multiple formulations described in the patent properties, has identified potential product candidates, and commenced IND enabling studies. scPharmaceuticals has additional U.S. patent applications pending that cover various methods of use of such or similar formulations of furosemide for treatment of congestion in patients with heart failure and edema in patients with kidney disease. The Company is also pursuing similar patent protection outside of the United States.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. Independent Director William Abraham was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • May 12Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.77m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.Breakeven Date Change • May 03Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 2.9% per year to 2024. The company is expected to make a profit of US$11.3m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 24No longer forecast to breakevenThe 5 analysts covering scPharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$2.85m in 2025. New consensus forecast suggests the company will make a loss of US$517.8k in 2025.お知らせ • Jan 31scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial UpdatescPharmaceuticals Inc. announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital. Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.97m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.お知らせ • Dec 20scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial OfficerscPharmaceuticals Inc. announced the appointment of Rachael Nokes as Chief Financial Officer. Ms. Nokes previously served as scPharmaceuticals’ Senior Vice President of Finance. Ms. Nokes is a senior financial executive with more than 20 years of experience, primarily in the life science industry. She joined scPharmaceuticals in 2014 from BG Medicine Inc., a publicly traded medical device company, where she was Director of Accounting. At BG Medicine, Ms. Nokes had significant responsibilities related to securing and managing several rounds of financing from various venture capital and other funding sources, culminating in the company’s initial public offering in early 2011. She was also instrumental in transitioning the finance organization from a privately held model to one capable of meeting the requirements for publicly traded entities, including SEC reporting and the implementation of Sarbanes Oxley. Prior to BG Medicine, Rachael held positions within Oak Industries Inc., a publicly traded supplier of components to the communications industry, and PriceWaterhouseCoopers, where she began her career as an auditor. She received a B.S. in Accounting from the Carroll School of Management at Boston College and an M.S. in Finance from Bentley University.お知らせ • Nov 24scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million.scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,620,000 Price\Range: $5.25 Discount Per Security: $0.315 Security Name: Prefunded Warrants Security Type: Equity Warrant Securities Offered: 2,905,000 Price\Range: $5.249 Discount Per Security: $0.315お知らせ • Nov 10scPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022scPharmaceuticals Inc. revised earnings guidance for the year 2022. Based on its current operating plan, the Company has adjusted its 2022 net loss to $38 to $41 million, a decrease over prior guidance of $43 to $48 million.お知らせ • Oct 27scPharmaceuticals Inc. to Report Q3, 2022 Results on Nov 09, 2022scPharmaceuticals Inc. announced that they will report Q3, 2022 results on Nov 09, 2022お知らせ • Oct 11+ 1 more updatescPharmaceuticals Inc. announced that it expects to receive $100 million in funding from Oaktree Capital Management, L.P.scPharmaceuticals Inc. announced that it has entered into a binding term sheet with respect to a $100 million secured debt facility on October 10, 2022. The transaction will include participation from new investor funds managed by Oaktree Capital Management, L.P. The transaction is subject to the parties’ execution of definitive agreements and customary closing conditions to be stipulated therein.お知らせ • Jul 13scPharmaceuticals Inc. Announces Positive Results from the at Home-HF Phase 2 Pilot Study in Heart FailurescPharmaceuticals Inc. announced positive results from the AT HOME-HF Pilot study, a Phase 2, multicenter, randomized study that compared scPharmaceuticals’ investigational product, FUROSCIX (furosemide 80 mg/10 mL for subcutaneous administration), with a “treatment as usual” approach in chronic heart failure patients presenting to a heart failure clinic with worsening congestion and requiring augmented diuresis. The study enrolled 51 subjects, of which 34 received FUROSCIX and 17 received “treatment as usual.” There was a positive trend in the Finkelstein-Schoenfeld win ratio of the hierarchal primary composite endpoint consisting of cardiovascular death, heart failure hospitalizations, emergency department visits for heart failure and % change from baseline of NT-proBNP at day seven in the FUROSCIX group compared to the “treatment as usual” group across multiple analysis populations. Subjects randomized to FUROSCIX had a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to “treatment as usual” at day 30. All pre-defined secondary endpoints measuring symptoms of congestion, quality of life and functional status favored the FUROSCIX group and included a two kilogram greater weight loss at day three and a 12-point increase in the 12 item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) summary scores at day 7 and day 30. There were 11 subjects that experienced 21 adverse events during the 30-day study period that were determined by the investigator to be related to FUROSCIX. The most common related adverse event was infusion site pain that was mild in severity. There was one serious adverse event (dehydration) that was assessed by the investigator as possibly related to FUROSCIX, which resolved. During the 30-day study period, there was one death (sudden cardiac death) in the FUROSCIX group which occurred on study day 30 and was assessed by the investigator to be not related to FUROSCIX.お知らせ • May 18+ 1 more updatescPharmaceuticals Inc. Provides Earnings Guidance for the Year 2022scPharmaceuticals Inc. provided earnings guidance for the year 2022, For the year, the company expects net loss to be $43 million to $48 million.お知らせ • Apr 12scPharmaceuticals Inc. Announces Resubmission of Furoscix® New Drug ApplicationscPharmaceuticals Inc. announced that the company has resubmitted its New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking marketing approval for FUROSCIX for the treatment of decompensated heart failure. In addition, West Pharmaceutical Services Inc. has completed all development activities and submitted the Device Master File in support of the FUROSCIX NDA. The company is advancing its commercial readiness activities in anticipation of a potential Fourth Quarter commercial launch, if approved. These include: Finalizing physician, payer and pricing research; Communicating FUROSCIX data, including FREEDOM-HF data, to pharmacy benefit managers and health plans through its product dossier; Finalizing FUROSCIX distribution partners; and Reinitiating commercial staffing to support anticipated Fourth Quarter 2022 launch, if approved.お知らせ • Sep 11scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021scPharmaceuticals Inc. announced that data from its recently-completed FREEDOM-HF clinical trial will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021. In the FREEDOM-HF study, heart failure (HF) patients with mild to moderate volume overload (despite oral diuretic use) and treated with subcutaneous FUROSCIX were successfully managed in the outpatient setting resulting in significantly reduced HF-related and overall healthcare costs through reduction of HF-related hospitalizations and rehospitalizations. Following its Type-C meeting with the FDA in June, aligned with the agency on the regulatory path forward, are well financed with more than $90 million on hand as of June 30, 2021, and remain on track to re-submit New Drug Application (NDA) in the fourth quarter of this year.お知らせ • Aug 12scPharmaceuticals Inc. Provides Earnings Guidance for the Year 2021scPharmaceuticals Inc. provided earnings guidance for the year 2021. Based on its current operating plan, the Company expects its net loss for 2021 to be in the range of $30.0 to $34.0 million for the fiscal year, a decrease over prior guidance of $32.0 to $36.0 million.お知らせ • Jul 15scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF StudyscPharmaceuticals Inc. announced positive top-line results from its FREEDOM-HF study. FREEDOM-HF was a prospective clinical trial evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure. Patients were treated with FUROSCIX®, investigational product, post-discharge from the emergency department compared to a historical comparator group that was treated with intravenous furosemide in the inpatient hospital setting. Based on the results from a planned, prespecified interim analysis conducted to confirm the final sample size, and following input from statisticians, principal investigators, payer advisors and Health Economics and Outcomes Research (HEOR) experts, enrollment was stopped on May 17, 2021, prior to the enrollment target of 34 patients. This decision was made due to the highly statistically significant reduction observed in 30-day heart failure-related costs in patients who received FUROSCIX in the interim analysis. The final analysis included 24 subjects treated with FUROSCIX and 66 matched comparators based on seven variables associated with hospitalization. Comparator patients hospitalized for 72 hours or less were identified, and costs were derived from service-level claims utilizing IBM® MarketScan® Research Databases which utilizes coding to standardize financial data from fully paid and adjudicated claims. The mean difference in heart failure-related costs between the two groups was $17,753 per study subject, with a p-value of p<0.0001 (95% CI: -$23,660, -$11,846), favoring the FUROSCIX group. This difference in costs was driven primarily by hospitalization costs. Per protocol, all subjects (24/24) who were enrolled in the study and received FUROSCIX did not require an initial heart failure hospitalization, and all but one (95.8%) remained out of the hospital for heart failure for the subsequent 30-day period. In the comparator group, 100% of the patients were initially hospitalized and 10.6% had a heart failure-related readmission. As part of the study design, all FUROSCIX patients were required to have at least one heart failure related clinic visit during the study period. In the comparator group, 34.9% of subjects had a heart failure related clinic visit. Since the price for FUROSCIX has not been established, the difference in costs does not include the cost of FUROSCIX. Additional analyses, including 30-day overall healthcare cost, quality of life as well as patient and caregiver satisfaction, are ongoing and complete data will be submitted for publication or presentation at an upcoming scientific meeting. The most common adverse events with FUROSCIX were infusion site pain, bruising and dizziness and no serious adverse events related to FUROSCIX were observed.お知らせ • Jul 03scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®scPharmaceuticals Inc. announced that on June 30, 2021 the Company received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the requirements for resubmission of the FUROSCIX New Drug Application (NDA). Based on guidance the Company received during the meeting and subsequently contained within the meeting minutes, the Company is moving forward with its original plan to conduct the required bench testing for the West Pharmaceutical Services’ (West) SmartDose® Gen II on-body drug delivery system that is used to deliver FUROSCIX to heart failure patients. Importantly, the FDA has not requested modifications to the device.お知らせ • Jun 28+ 6 more updatesscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E IndexscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E IndexBreakeven Date Change • May 16Forecast to breakeven in 2024The 2 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$14.2m in 2024. Average annual earnings growth of 55% is required to achieve expected profit on schedule.お知らせ • May 13Scpharmaceuticals Inc. Announces Earnings Guidance for 2021scPharmaceuticals Inc. announced Based on its current operating plan, the Company expects the net loss for 2021 to be in the range of $32.0 to $36.0 million for the fiscal year.お知らせ • Mar 25Scpharmaceuticals Inc. Provides Earnings Forecasts for the Year 2021scPharmaceuticals Inc. provided earnings forecasts for the year 2021. For the period, the company forecasts net loss to be $32 to $36 million.お知らせ • Feb 18scPharmaceuticals Inc. Appoints William T. Abraham, M.D., to Its Board of DirectorsscPharmaceuticals Inc. announced the appointment of William T. Abraham, M.D., to the company’s Board of Directors. Dr. Abraham currently serves as Professor of Internal Medicine (Cardiology), Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients.Is New 90 Day High Low • Dec 08New 90-day low: €4.40The company is down 36% from its price of €6.85 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Dec 06Scpharmaceuticals Inc. Announces Resignation of Mason W. Freeman as A Member of the Board and All Committees, Effective as of December 15, 2020scPharmaceuticals Inc. announced that Mason W. Freeman, M.D. informed the Board of Directors of scPharmaceuticals Inc. of his resignation as a member of the Board and all committees of the Board, effective as of December 15, 2020. There are no disagreements between Dr. Freeman and the Company on any matter relating to the Company's operations, policies or practices.お知らせ • Nov 18Scpharmaceuticals Inc. Announces Financial Guidance for 2020scPharmaceuticals Inc. announced that based on the current operating plan, the Company expects the net loss for 2020 to be lower than prior guidance and in the range of $34.0 to $37.0 million for the fiscal year.Is New 90 Day High Low • Nov 11New 90-day high: €7.75The company is up 16% from its price of €6.70 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 24New 90-day high: €7.60The company is up 21% from its price of €6.30 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Oct 10scPharmaceuticals Inc. Provides Business Update on FUROSCIXscPharmaceuticals Inc. provided a business update on FUROSCIX®, its investigational proprietary formulation of furosemide for subcutaneous administration. The Company has submitted twelve-month drug stability data to the U.S. Food and Drug Administration (FDA). Pursuant to an agreement with the FDA, scPharmaceuticals was permitted to submit its New Drug Application (NDA) with nine months of drug stability data and submit the remining three months during the FDA’s review. All drug stability data has now been submitted. To prepare for the launch of FUROSCIX, if approved, the Company has made key additions to its commercial team, including vice presidents of marketing, sales and market access. In addition, recruitment for the Company’s field sales team is ongoing and remains closely aligned with currently anticipated regulatory timelines.お知らせ • Sep 18Scpharmaceuticals Files New Drug Application with Fda Seeking Approval of FUROSCIX® for the Treatment of Congestion Due to Fluid Overload in Adult Patients with Worsening New York Heart Association Class II and Class III Heart Failure Who Display Reduced Responsiveness to Oral Diuretics and Who Do Not Require HospitalizationscPharmaceuticals Inc. has filed a 505(b)(2) New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval of FUROSCIX® for the treatment of congestion due to fluid overload in adult patients with worsening New York Heart Association (NYHA) Class II and Class III heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization. scPharmaceuticals recently announced that its resubmission has been accepted for review and assigned a Prescription Drug User-Fee Act (PDUFA) target action date of December 30, 2020.お知らせ • Jul 02scPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Value IndexscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Value Index業績と収益の成長予測DB:2SX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2027186375729412/31/2026128-92-7412/31/202573-60-53-5246/30/202550-92-66-66N/A3/31/202542-91-70-70N/A12/31/202436-85-71-71N/A9/30/202430-80-71-71N/A6/30/202424-61-67-67N/A3/31/202418-58-60-60N/A12/31/202314-55-59-59N/A9/30/20237-50-56-56N/A6/30/20234-45-51-51N/A3/31/20232-40-44-44N/A12/31/2022N/A-37-35-35N/A9/30/2022N/A-35-30-30N/A6/30/2022N/A-31-27-27N/A3/31/2022N/A-29-26-26N/A12/31/2021N/A-28-27-27N/A9/30/2021N/A-28-29-29N/A6/30/2021N/A-31-29-29N/A3/31/2021N/A-32-29-29N/A12/31/2020N/A-32-28-28N/A9/30/2020N/A-35-33-33N/A6/30/2020N/A-32-34-34N/A3/31/2020N/A-31-32-32N/A12/31/2019N/A-33-30-30N/A9/30/2019N/A-27-21-21N/A6/30/2019N/A-27-21-21N/A3/31/2019N/A-29N/A-26N/A12/31/2018N/A-29N/A-29N/A9/30/2018N/A-31N/A-29N/A6/30/2018N/A-31N/A-29N/A3/31/2018N/A-28N/A-27N/A12/31/2017N/A-24N/A-23N/A9/30/2017N/A-22N/A-22N/A6/30/2017N/A-26N/A-20N/A3/31/2017N/A-24N/A-17N/A12/31/2016N/A-24N/A-15N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2SXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 1.4% ) よりも高い成長率であると考えられます。収益対市場: 2SX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 2SX今後 3 年以内に収益を上げることが予想されます。収益対市場: 2SXの収益 ( 34% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 2SXの収益 ( 34% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2SXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/08 18:04終値2025/10/06 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋scPharmaceuticals Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullBMO Capital Markets Equity ResearchGary NachmanBMO Capital Markets Equity ResearchChase KnickerbockerCraig-Hallum Capital Group LLC3 その他のアナリストを表示
お知らせ • Jan 11scPharmaceuticals Inc. Provides Preliminary FUROSCIX Net Revenue Guidance for the Fourth Quarter and Full Year 2024scPharmaceuticals Inc. provided preliminary FUROSCIX net revenue guidance for the fourth quarter and full year 2024. The company expected preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12.0 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range. Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range.
Breakeven Date Change • Mar 27Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 31% per year to 2025. The company is expected to make a profit of US$39.9m in 2026. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
お知らせ • Jan 05scPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023scPharmaceuticals Inc. provided revenue guidance for the full year 2023. For the period, the company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.4m in 2026. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 11Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$4.74m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
Breakeven Date Change • May 12Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.77m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
お知らせ • Oct 18scPharmaceuticals Inc. Files Form 15scPharmaceuticals Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
お知らせ • Oct 09scPharmaceuticals Inc.(NasdaqGM:SCPH) dropped from NASDAQ Composite IndexscPharmaceuticals Inc. has been dropped from the NASDAQ Composite Index .
お知らせ • Oct 08MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH).MannKind Corporation (NasdaqGM:MNKD) entered into a definitive Agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. As on October 6, 2025, the tender offer expired and pursuant to the offer 73.47% shares where validly tendered. Jefferies LLC acted as financial advisor for MannKind Corporation. The team of Cooley LLP led by Barbara Borden, Rowook Park, Julia Kim, Mischi a Marca and Adam Longenbach acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. The team of Latham & Watkins LLP led by Wesley Holmes, Scott Shean, Bret Stancil, Elisabeth Martin, Peter Handrinos, Alexandra McArthur, Josh Friedman, Katharine Moir, Betty Pang, Chad Jennings, Elizabeth Ohacted, Heather Deixler, Patrick English, Kristin Murphy and Steven Chinowsky as legal advisor for scPharmaceuticals Inc. MannKind Corporation (NasdaqGM:MNKD) completed the acquisition of scPharmaceuticals Inc. (NasdaqGS:SCPH) on October 7, 2025.
お知らせ • Oct 07+ 20 more updatesscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from NASDAQ Biotechnology IndexscPharmaceuticals Inc removed from NASDAQ Biotechnology Index.
お知らせ • Aug 25MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million.MannKind Corporation (NasdaqGM:MNKD) entered into a definitive agreement to acquire scPharmaceuticals Inc. (NasdaqGS:SCPH) for approximately $290 million on August 24, 2025. As part of agreement, MannKind Corporation will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals's common stock, at a price per share of (i) $5.35 in cash, without interest, subject to any applicable withholding taxes and (ii) one non-tradeable contingent value right (CVR), which represents the right to receive certain milestone payments of up to an aggregate of $1.00 in cash, payable upon achieving specific regulatory and net sales milestones. In case of termination of transaction, scPharmaceuticals will pay a termination fee of $9.48 million. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals. MannKind and Blackstone amended their recently announced strategic financing agreement to provide $175 million of additional funding to support the acquisition. The transaction is subject to approval by regulatory board / committee, minimum tender and all applicable waiting periods under the HSR Act and the Required Antitrust Approvals shall have expired or been terminated and any approvals or clearances required thereunder shall have been obtained. The board of directors of the scPharmaceuticalst unanimously recommends that stockholders accept the Offer. The deal has been unanimously approved by the boards of MannKind Corporation and scPharmaceuticals. The transaction is expected to complete in fourth quarter of 2025. Jefferies LLC acted as financial advisor for MannKind Corporation. Barbara Borden and Rowook Park of Cooley LLP acted as legal advisor for MannKind Corporation. Leerink Partners LLC acted as financial advisor for scPharmaceuticals Inc. Scott Shean, Wesley Holmes and Bret Stancil of Latham & Watkins LLP acted as legal advisor for scPharmaceuticals Inc.
お知らせ • Aug 14scPharmaceuticals Inc. Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111scPharmaceuticals Inc. announced that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.
お知らせ • Aug 01scPharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025scPharmaceuticals Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
お知らせ • May 08scPharmaceuticals Inc. to Report Q1, 2025 Results on May 14, 2025scPharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025
お知らせ • Apr 22scPharmaceuticals Inc., Annual General Meeting, Jun 03, 2025scPharmaceuticals Inc., Annual General Meeting, Jun 03, 2025.
お知らせ • Mar 13scPharmaceuticals Inc. to Report Q4, 2024 Results on Mar 19, 2025scPharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 19, 2025
お知らせ • Mar 07scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX®? Indication to Include the Treatment of Edema in Patients with Chronic Kidney DiseasescPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX®? to expand the indication to include treatment of edema in patients with chronic kidney disease (CKD). FUROSCIX (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the treatment of edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.
お知らせ • Jan 11scPharmaceuticals Inc. Provides Preliminary FUROSCIX Net Revenue Guidance for the Fourth Quarter and Full Year 2024scPharmaceuticals Inc. provided preliminary FUROSCIX net revenue guidance for the fourth quarter and full year 2024. The company expected preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12.0 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range. Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range.
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.75 loss per share (vs US$0.40 loss in 3Q 2023)Third quarter 2024 results: US$0.75 loss per share (further deteriorated from US$0.40 loss in 3Q 2023). Revenue: US$10.0m (up 164% from 3Q 2023). Net loss: US$35.1m (loss widened 125% from 3Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 07scPharmaceuticals Inc. to Report Q3, 2024 Results on Nov 13, 2024scPharmaceuticals Inc. announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Aug 15Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.37 loss in 2Q 2023)Second quarter 2024 results: US$0.44 loss per share (further deteriorated from US$0.37 loss in 2Q 2023). Revenue: US$8.05m (up 392% from 2Q 2023). Net loss: US$17.1m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
New Risk • Aug 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 34% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (34% increase in shares outstanding).
お知らせ • Aug 13+ 1 more updatescPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $49.9995 million.scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $49.9995 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 Price\Range: $4 Discount Per Security: $0.24 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 500,000 Price\Range: $3.999 Discount Per Security: $0.24
お知らせ • Aug 12scPharmaceuticals Inc. has filed a Follow-on Equity Offering.scPharmaceuticals Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Security Name: Pre-funded Warrants Security Type: Equity Warrant
お知らせ • Jul 25scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney DiseasescPharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025. In Type D meeting feedback provided by the FDA last year, the agency confirmed that no additional clinical studies would be needed to expand the indication, provided that the Company is able to demonstrate an adequate pharmacokinetic (PK) and pharmacodynamic (PD) bridge to the listed drug, furosemide injection, 10 mg/mL. FUROSCIX® (furosemide injection) 80 mg/10mL for subcutaneous use: FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The On-Body Infusor will deliver only an 80-mg dose of FUROSCIX. IMPORTANT SAFETY INFORMATION: FUROSCIX is contraindicated in patients with anuria, patients with a history of hypersensitivity to furosemide or medical adhesives and in patients with hepatic cirrhosis or ascites. Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital. Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
New Risk • May 15New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$60m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$60m). Share price has been volatile over the past 3 months (8.4% average weekly change).
お知らせ • May 09scPharmaceuticals Inc. to Report Q1, 2024 Results on May 14, 2024scPharmaceuticals Inc. announced that they will report Q1, 2024 results on May 14, 2024
お知らせ • Apr 28scPharmaceuticals Inc., Annual General Meeting, Jun 11, 2024scPharmaceuticals Inc., Annual General Meeting, Jun 11, 2024, at 12:30 US Eastern Standard Time. Agenda: To elect three Class I directors, namely Frederick Hudson, Leonard D. Schaeffer and Sara Bonstein, each to hold office until the 2027 annual meeting of stockholders and until their successor is duly elected and qualified, or until their earlier death, resignation or removal; to ratify the appointment of RSM US LLP as company's independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on an advisory (non-binding) basis, the compensation of company's named executive officers; to approve an amendment to the Second Amended and Restated Certificate of Incorporation to provide for the exculpation of officers from certain breaches of fiduciary duty to the extent permitted by the General Corporation Law of the State of Delaware; and to transact any other business that properly comes before the Annual Meeting (including any continuation, adjournment or postponement thereof).
Board Change • Apr 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Independent Director William Abraham was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 25scPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) InjectionscPharmaceuticals Inc. announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector. The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility. If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
Breakeven Date Change • Mar 27Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 31% per year to 2025. The company is expected to make a profit of US$39.9m in 2026. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
お知らせ • Mar 14scPharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $50 million.scPharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 07scPharmaceuticals Inc. to Report Q4, 2023 Results on Mar 13, 2024scPharmaceuticals Inc. announced that they will report Q4, 2023 results on Mar 13, 2024
お知らせ • Jan 05scPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023scPharmaceuticals Inc. provided revenue guidance for the full year 2023. For the period, the company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 6 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$42.4m in 2026. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
お知らせ • Nov 02scPharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023scPharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 08, 2023
New Risk • Nov 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (US$3.7m revenue).
お知らせ • Sep 20Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth InitiativesscPharmaceuticals Inc. announced that the Company has received positive feedback from the U.S. Food and Drug Administration (FDA) on two key long-term growth initiatives. The Company announced FDA feedback from a Type C meeting pertaining to the development of an 80mg/1mL auto-injector intended to provide an additional option to the on-body infusor for treatment of congestion due to fluid overload in eligible adult patients who do not require hospitalization. The Company expects that an auto-injector, if successfully developed and approved, would reduce manufacturing costs compared to the current on-body infusor and confer environmental advantages. scPharmaceuticals plans to report data from a pivotal pharmacokinetic (PK) study in first half of 2024, and, if successful, targets submitting a Supplemental New Drug Application (sNDA) to the FDA by the end of 2024. The Company also announced feedback from a Type D meeting with the FDA pertaining to the potential expansion of the FUROSCIX label to include treatment of edema due to fluid overload in patients with CKD. In its feedback, the FDA confirmed that no additional clinical studies are needed to expand the indication, provided that the Company demonstrates an adequate PK and pharmacodynamic bridge to the listed drug, furosemide injection, 10 mg/mL. CKD is a progressive disease characterized by worsening renal function over time, resulting in frequent episodes of fluid overload that are treated with loop diuretics.
Breakeven Date Change • Aug 11Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$4.74m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
お知らせ • Aug 04scPharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023scPharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023
お知らせ • Aug 03scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication ExpansionscPharmaceuticals Inc. announced that the Company has received positive Type C meeting feedback from the US Food and Drug Administration (FDA) regarding the potential expansion of the FUROSCIX(R) indication to allow for use in New York Heart Association (NYHA) Class IV heart failure patients. FUROSCIX is currently indicated for the treatment of congestion due to fluid overload in adult patients with NYHA Class II and Class III chronic heart failure. The Company also announced the issuance of U.S. patents covering concentrated formulations of furosemide. This enables the possibility of developing additional furosemide formulations for subcutaneous administration that will provide clinicians with additional dosing flexibility. The Company has completed initial solubility and stability studies on multiple formulations described in the patent properties, has identified potential product candidates, and commenced IND enabling studies. scPharmaceuticals has additional U.S. patent applications pending that cover various methods of use of such or similar formulations of furosemide for treatment of congestion in patients with heart failure and edema in patients with kidney disease. The Company is also pursuing similar patent protection outside of the United States.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. Independent Director William Abraham was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • May 12Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.77m in 2025. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
Breakeven Date Change • May 03Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 2.9% per year to 2024. The company is expected to make a profit of US$11.3m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 24No longer forecast to breakevenThe 5 analysts covering scPharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$2.85m in 2025. New consensus forecast suggests the company will make a loss of US$517.8k in 2025.
お知らせ • Jan 31scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial UpdatescPharmaceuticals Inc. announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. FUROSCIX® is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy. Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. In patients with hepatic cirrhosis and ascites, sudden alterations of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma. Treatment in such patients is best initiated in the hospital. Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment. The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 5 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.97m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
お知らせ • Dec 20scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial OfficerscPharmaceuticals Inc. announced the appointment of Rachael Nokes as Chief Financial Officer. Ms. Nokes previously served as scPharmaceuticals’ Senior Vice President of Finance. Ms. Nokes is a senior financial executive with more than 20 years of experience, primarily in the life science industry. She joined scPharmaceuticals in 2014 from BG Medicine Inc., a publicly traded medical device company, where she was Director of Accounting. At BG Medicine, Ms. Nokes had significant responsibilities related to securing and managing several rounds of financing from various venture capital and other funding sources, culminating in the company’s initial public offering in early 2011. She was also instrumental in transitioning the finance organization from a privately held model to one capable of meeting the requirements for publicly traded entities, including SEC reporting and the implementation of Sarbanes Oxley. Prior to BG Medicine, Rachael held positions within Oak Industries Inc., a publicly traded supplier of components to the communications industry, and PriceWaterhouseCoopers, where she began her career as an auditor. She received a B.S. in Accounting from the Carroll School of Management at Boston College and an M.S. in Finance from Bentley University.
お知らせ • Nov 24scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million.scPharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50.003345 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,620,000 Price\Range: $5.25 Discount Per Security: $0.315 Security Name: Prefunded Warrants Security Type: Equity Warrant Securities Offered: 2,905,000 Price\Range: $5.249 Discount Per Security: $0.315
お知らせ • Nov 10scPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022scPharmaceuticals Inc. revised earnings guidance for the year 2022. Based on its current operating plan, the Company has adjusted its 2022 net loss to $38 to $41 million, a decrease over prior guidance of $43 to $48 million.
お知らせ • Oct 27scPharmaceuticals Inc. to Report Q3, 2022 Results on Nov 09, 2022scPharmaceuticals Inc. announced that they will report Q3, 2022 results on Nov 09, 2022
お知らせ • Oct 11+ 1 more updatescPharmaceuticals Inc. announced that it expects to receive $100 million in funding from Oaktree Capital Management, L.P.scPharmaceuticals Inc. announced that it has entered into a binding term sheet with respect to a $100 million secured debt facility on October 10, 2022. The transaction will include participation from new investor funds managed by Oaktree Capital Management, L.P. The transaction is subject to the parties’ execution of definitive agreements and customary closing conditions to be stipulated therein.
お知らせ • Jul 13scPharmaceuticals Inc. Announces Positive Results from the at Home-HF Phase 2 Pilot Study in Heart FailurescPharmaceuticals Inc. announced positive results from the AT HOME-HF Pilot study, a Phase 2, multicenter, randomized study that compared scPharmaceuticals’ investigational product, FUROSCIX (furosemide 80 mg/10 mL for subcutaneous administration), with a “treatment as usual” approach in chronic heart failure patients presenting to a heart failure clinic with worsening congestion and requiring augmented diuresis. The study enrolled 51 subjects, of which 34 received FUROSCIX and 17 received “treatment as usual.” There was a positive trend in the Finkelstein-Schoenfeld win ratio of the hierarchal primary composite endpoint consisting of cardiovascular death, heart failure hospitalizations, emergency department visits for heart failure and % change from baseline of NT-proBNP at day seven in the FUROSCIX group compared to the “treatment as usual” group across multiple analysis populations. Subjects randomized to FUROSCIX had a 37% reduction in the risk of a heart failure hospitalization relative to patients randomized to “treatment as usual” at day 30. All pre-defined secondary endpoints measuring symptoms of congestion, quality of life and functional status favored the FUROSCIX group and included a two kilogram greater weight loss at day three and a 12-point increase in the 12 item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) summary scores at day 7 and day 30. There were 11 subjects that experienced 21 adverse events during the 30-day study period that were determined by the investigator to be related to FUROSCIX. The most common related adverse event was infusion site pain that was mild in severity. There was one serious adverse event (dehydration) that was assessed by the investigator as possibly related to FUROSCIX, which resolved. During the 30-day study period, there was one death (sudden cardiac death) in the FUROSCIX group which occurred on study day 30 and was assessed by the investigator to be not related to FUROSCIX.
お知らせ • May 18+ 1 more updatescPharmaceuticals Inc. Provides Earnings Guidance for the Year 2022scPharmaceuticals Inc. provided earnings guidance for the year 2022, For the year, the company expects net loss to be $43 million to $48 million.
お知らせ • Apr 12scPharmaceuticals Inc. Announces Resubmission of Furoscix® New Drug ApplicationscPharmaceuticals Inc. announced that the company has resubmitted its New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking marketing approval for FUROSCIX for the treatment of decompensated heart failure. In addition, West Pharmaceutical Services Inc. has completed all development activities and submitted the Device Master File in support of the FUROSCIX NDA. The company is advancing its commercial readiness activities in anticipation of a potential Fourth Quarter commercial launch, if approved. These include: Finalizing physician, payer and pricing research; Communicating FUROSCIX data, including FREEDOM-HF data, to pharmacy benefit managers and health plans through its product dossier; Finalizing FUROSCIX distribution partners; and Reinitiating commercial staffing to support anticipated Fourth Quarter 2022 launch, if approved.
お知らせ • Sep 11scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021scPharmaceuticals Inc. announced that data from its recently-completed FREEDOM-HF clinical trial will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021. In the FREEDOM-HF study, heart failure (HF) patients with mild to moderate volume overload (despite oral diuretic use) and treated with subcutaneous FUROSCIX were successfully managed in the outpatient setting resulting in significantly reduced HF-related and overall healthcare costs through reduction of HF-related hospitalizations and rehospitalizations. Following its Type-C meeting with the FDA in June, aligned with the agency on the regulatory path forward, are well financed with more than $90 million on hand as of June 30, 2021, and remain on track to re-submit New Drug Application (NDA) in the fourth quarter of this year.
お知らせ • Aug 12scPharmaceuticals Inc. Provides Earnings Guidance for the Year 2021scPharmaceuticals Inc. provided earnings guidance for the year 2021. Based on its current operating plan, the Company expects its net loss for 2021 to be in the range of $30.0 to $34.0 million for the fiscal year, a decrease over prior guidance of $32.0 to $36.0 million.
お知らせ • Jul 15scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF StudyscPharmaceuticals Inc. announced positive top-line results from its FREEDOM-HF study. FREEDOM-HF was a prospective clinical trial evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure. Patients were treated with FUROSCIX®, investigational product, post-discharge from the emergency department compared to a historical comparator group that was treated with intravenous furosemide in the inpatient hospital setting. Based on the results from a planned, prespecified interim analysis conducted to confirm the final sample size, and following input from statisticians, principal investigators, payer advisors and Health Economics and Outcomes Research (HEOR) experts, enrollment was stopped on May 17, 2021, prior to the enrollment target of 34 patients. This decision was made due to the highly statistically significant reduction observed in 30-day heart failure-related costs in patients who received FUROSCIX in the interim analysis. The final analysis included 24 subjects treated with FUROSCIX and 66 matched comparators based on seven variables associated with hospitalization. Comparator patients hospitalized for 72 hours or less were identified, and costs were derived from service-level claims utilizing IBM® MarketScan® Research Databases which utilizes coding to standardize financial data from fully paid and adjudicated claims. The mean difference in heart failure-related costs between the two groups was $17,753 per study subject, with a p-value of p<0.0001 (95% CI: -$23,660, -$11,846), favoring the FUROSCIX group. This difference in costs was driven primarily by hospitalization costs. Per protocol, all subjects (24/24) who were enrolled in the study and received FUROSCIX did not require an initial heart failure hospitalization, and all but one (95.8%) remained out of the hospital for heart failure for the subsequent 30-day period. In the comparator group, 100% of the patients were initially hospitalized and 10.6% had a heart failure-related readmission. As part of the study design, all FUROSCIX patients were required to have at least one heart failure related clinic visit during the study period. In the comparator group, 34.9% of subjects had a heart failure related clinic visit. Since the price for FUROSCIX has not been established, the difference in costs does not include the cost of FUROSCIX. Additional analyses, including 30-day overall healthcare cost, quality of life as well as patient and caregiver satisfaction, are ongoing and complete data will be submitted for publication or presentation at an upcoming scientific meeting. The most common adverse events with FUROSCIX were infusion site pain, bruising and dizziness and no serious adverse events related to FUROSCIX were observed.
お知らせ • Jul 03scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®scPharmaceuticals Inc. announced that on June 30, 2021 the Company received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the requirements for resubmission of the FUROSCIX New Drug Application (NDA). Based on guidance the Company received during the meeting and subsequently contained within the meeting minutes, the Company is moving forward with its original plan to conduct the required bench testing for the West Pharmaceutical Services’ (West) SmartDose® Gen II on-body drug delivery system that is used to deliver FUROSCIX to heart failure patients. Importantly, the FDA has not requested modifications to the device.
お知らせ • Jun 28+ 6 more updatesscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E IndexscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell 3000E Index
Breakeven Date Change • May 16Forecast to breakeven in 2024The 2 analysts covering scPharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$14.2m in 2024. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
お知らせ • May 13Scpharmaceuticals Inc. Announces Earnings Guidance for 2021scPharmaceuticals Inc. announced Based on its current operating plan, the Company expects the net loss for 2021 to be in the range of $32.0 to $36.0 million for the fiscal year.
お知らせ • Mar 25Scpharmaceuticals Inc. Provides Earnings Forecasts for the Year 2021scPharmaceuticals Inc. provided earnings forecasts for the year 2021. For the period, the company forecasts net loss to be $32 to $36 million.
お知らせ • Feb 18scPharmaceuticals Inc. Appoints William T. Abraham, M.D., to Its Board of DirectorsscPharmaceuticals Inc. announced the appointment of William T. Abraham, M.D., to the company’s Board of Directors. Dr. Abraham currently serves as Professor of Internal Medicine (Cardiology), Physiology and Cell Biology and College of Medicine Distinguished Professor at The Ohio State University as well as Chief Medical Officer at V-Wave Ltd., a privately held developer of percutaneous implantable therapeutic devices for chronic heart failure patients.
Is New 90 Day High Low • Dec 08New 90-day low: €4.40The company is down 36% from its price of €6.85 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Dec 06Scpharmaceuticals Inc. Announces Resignation of Mason W. Freeman as A Member of the Board and All Committees, Effective as of December 15, 2020scPharmaceuticals Inc. announced that Mason W. Freeman, M.D. informed the Board of Directors of scPharmaceuticals Inc. of his resignation as a member of the Board and all committees of the Board, effective as of December 15, 2020. There are no disagreements between Dr. Freeman and the Company on any matter relating to the Company's operations, policies or practices.
お知らせ • Nov 18Scpharmaceuticals Inc. Announces Financial Guidance for 2020scPharmaceuticals Inc. announced that based on the current operating plan, the Company expects the net loss for 2020 to be lower than prior guidance and in the range of $34.0 to $37.0 million for the fiscal year.
Is New 90 Day High Low • Nov 11New 90-day high: €7.75The company is up 16% from its price of €6.70 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 24New 90-day high: €7.60The company is up 21% from its price of €6.30 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Oct 10scPharmaceuticals Inc. Provides Business Update on FUROSCIXscPharmaceuticals Inc. provided a business update on FUROSCIX®, its investigational proprietary formulation of furosemide for subcutaneous administration. The Company has submitted twelve-month drug stability data to the U.S. Food and Drug Administration (FDA). Pursuant to an agreement with the FDA, scPharmaceuticals was permitted to submit its New Drug Application (NDA) with nine months of drug stability data and submit the remining three months during the FDA’s review. All drug stability data has now been submitted. To prepare for the launch of FUROSCIX, if approved, the Company has made key additions to its commercial team, including vice presidents of marketing, sales and market access. In addition, recruitment for the Company’s field sales team is ongoing and remains closely aligned with currently anticipated regulatory timelines.
お知らせ • Sep 18Scpharmaceuticals Files New Drug Application with Fda Seeking Approval of FUROSCIX® for the Treatment of Congestion Due to Fluid Overload in Adult Patients with Worsening New York Heart Association Class II and Class III Heart Failure Who Display Reduced Responsiveness to Oral Diuretics and Who Do Not Require HospitalizationscPharmaceuticals Inc. has filed a 505(b)(2) New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval of FUROSCIX® for the treatment of congestion due to fluid overload in adult patients with worsening New York Heart Association (NYHA) Class II and Class III heart failure who display reduced responsiveness to oral diuretics and who do not require hospitalization. scPharmaceuticals recently announced that its resubmission has been accepted for review and assigned a Prescription Drug User-Fee Act (PDUFA) target action date of December 30, 2020.
お知らせ • Jul 02scPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Value IndexscPharmaceuticals Inc.(NasdaqGS:SCPH) dropped from Russell Microcap Value Index